Home » Posts tagged 'investor' (Page 2)
Tag Archives: investor
#KAV Kavango Resources PLC – Corporate update & expiry of warrants
Kavango Resources plc (LSE:KAV), the Southern Africa focussed metals exploration company, is pleased to provide the following corporate update.
Progress with new acquisition
Kavango confirms it is in late-stage discussions for a potential exclusive 2-year option to acquire a gold exploration and development project in Zimbabwe (the “Option”). The project area covers a number of contiguous gold claims over a 3.4km strike that has supported historic high-grade underground mining and more recent surface small-scale mining op(the “Project Area”).
The Project Area has never been explored using modern methods or technology. Provisional terms of the Option would allow Kavango to perform unrestricted field due diligence (exploration and drilling), ahead of deciding whether to exercise the Option.
Kavango has completed extensive preliminary due diligence ahead of negotiating the Option, including two field visits to the Project Area.
Potential £6,000,000 conditional equity investment into Kavango
In parallel to the new acquisition discussions, Kavango has been in discussions with a single investor concerning a possible £6,000,000 conditional equity investment into the Company via a non-brokered direct subscription (the “Proposed Subscription”).
Should terms be finalised and agreed, the Company expects to complete the Proposed Subscription at 1p per share. Full completion of the Proposed Subscription would be subject to (i) approval by the Financial Conduct Authority of a prospectus; (ii) approval by shareholders of a waiver in accordance with Rule 9 of the Takeover Code; and (iii) the Company having the necessary authorities to issue the subscription shares.
Expiry of April 2020 warrants
On 15 April 2020, Kavango announced a £358,000 placing and subscription (the “April 2020 Placing”). As part of the April 2020 Placing, the Company issued “A” and “B” warrants on a 3-year term. All unexercised “A” and “B” warrants have now expired.
Further information in respect of the Company and its business interests is provided on the Company’s website at www.kavangoresources.com and on Twitter at #KAV.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Further information in respect of the Company and its business interests is provided on the Company’s website at www.kavangoresources.com and on Twitter at #KAV.
For further information please contact:
Kavango Resources plc
Ben Turney
+46 7697 406 06
First Equity (Broker)
+44 207 374 2212
Jason Robertson
#BRES Blencowe Resources PLC – Investor Webinar & Updated Presentation
Blencowe Resources (LSE:BRES), is pleased to announce that it will host a shareholder webinar and Q&A on Tuesday 9 May 2023 at 12:00pm UK time (19:00pm WST time).
The call will be hosted by Blencowe’s CEO, Mike Ralston who will discuss the Company’s recently announced news relating funding assistance for the further development of Blencowe’s Orom-Cross graphite project from the United States Government’s Development Finance Corporation.
Registration Details:
A recording of the webinar will also be made available on the Company’s website following the event. Investors are invited to register using the following link:
https://us02web.zoom.us/webinar/register/WN_AuIvebCoTJ-neLmgOWOaYQ
Shareholders who wish to do so are invited to submit questions via email to: info@blencoweresourcesplc.com
Latest Corporate Presentation:
An updated copy of the Company’s corporate presentation can be found on the Company’s website at:
https://blencoweresourcesplc.com/presentation/
Video Interview:
A link to a recent video interview Mike Ralston on the Proactive Investors platform is below:
Company Newsletter
Interested investors can also sign up for the Company Newsletter here:
https://blencoweresourcesplc.com/contact/
Contacts
Blencowe Resources Plc Sam Quinn (London Director) |
info@blencoweresourcesplc.com +44 (0)1624 681 250 |
Investor Enquiries Sasha Sethi
|
Tel: +44 (0) 7891 677 441 sasha@flowcomms.com
|
Tavira Financial Jonathan Evans
|
Tel: +44 (0)20 7100 5100 jonathan.evans@tavira.group |
First Equity Limited Jason Robertson |
Tel: +44 (0)20 7330 1883 jasonrobertson@firstequitylimited.com |
#TEK Tekcapital Plc – Notification of Investor Presentation
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF), the UK intellectual property investment group focused on transforming university technologies into valuable products that can improve people’s lives, is pleased to announce that Dr. Clifford Gross, the Company’s Chief Executive Officer, will be holding a live Investor Q&A session via the Investor Meet Company platform on 27 February 2023 at 4pm (UK Local time).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Tekcapital plc via:
https://www.investormeetcompany.com/tekcapital-plc/register-investor
Investors who already follow Tekcapital plc on the Investor Meet Company platform will automatically be invited.
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
Tekcapital Plc |
|
Via Flagstaff |
Clifford M. Gross, Ph.D. |
||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
|
+44 (0) 20 3470 0470 |
Richard Morrison/Charlie Bouverat (Corporate Finance) |
||
Abigail Wayne (Corporate Broking) |
||
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon |
Tekcapital@flagstaffcomms.com |
#TEK TekCapital PLC – Placing to raise £2.25 Million(C.US$2.7M)
Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives announces that it has raised a total of £2.25 million (c.US$2.7m) before expenses, in an oversubscribed placing from existing and new shareholders, by way of the issue of, in aggregate, 14,062,500 new ordinary shares of 0.4 pence each in the Company (the “Ordinary Shares”), at a price of 16 pence per share (the “Placing Shares”) (together, the “Placing”).
The net proceeds of the Placing will primarily be used to accelerate the growth of the Company’s portfolio companies. The Placing was undertaken by the Company’s broker SP Angel Corporate Finance LLP.
Key Highlights:
– £2.25m (US$2.7m) before expenses was raised by means of a fundraise through the issue of, in aggregate 14,062,500 Placing Shares at 16 pence per Placing Share.
Funds raised will be used as follows:
– £0.6m to build commercial inventory of MicroSalt Limited
– £1m to purchase autonomous shuttles for Guident’s Remote Control Monitoring Centre clients and for fabrication and testing of their regenerative shock absorbers for prospective clients
– the remainder of the funds raised will primarily be for additional working capital.
Admission and Total Voting Rights
Application has been made for the 14,062,500 Placing Shares to be admitted to trading on AIM (“Admission”). It is expected that Admission will become effective on or around 23 February 2023.
Following the issue of the 14,062,500 Placing Shares, which on Admission will rank pari passu with the existing Ordinary Shares, the total number of Ordinary Shares in issue with voting rights in the Company will be 164,754,828. There are no shares held in treasury.
The above figure of 164,754,828 Ordinary Shares may therefore be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc commented:
“We are pleased to announce this oversubscribed offering to facilitate the further good progress of our portfolio
companies.“
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
Tekcapital Plc |
Via Flagstaff |
|
Clifford M. Gross, Ph.D. |
||
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) |
+44 (0) 20 3470 0470 |
|
Richard Morrison/Charlie Bouverat (Corporate Finance) |
||
Abigail Wayne (Corporate Broking) |
||
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon |
|
#TEK TekCapital Plc investee co. #BELL Belluscura Plc – Year-end Trading Update
LONDON, U.K. AND PLANO, TX, U.S. (13 January 2023) Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen concentrator (“POC”) technology, provides a trading update for the year ended 31 December 2022.
The Group is pleased to announce that it has made considerable progress this year. Since the launch of the 1st generation X-PLOR in September 2021, the Group is now distributing throughout the US through multiple sales channels: Distributors and Durable Medical Equipment Providers both Online and Bricks and Mortar, Medical Supply Warehouses, Medical Device Intermediaries, Hospitals and Direct to Consumer.
In addition, the collaboration agreement with the VGM Group has already resulted in 17 new distribution agreements in the last 3 months, including the agreement with a leading durable medical equipment provider and distributor in the US, announced in September 2022, which serves nearly 2 million patients both online and through over 1,000 locations.
In December 2022 we also signed our first international distribution agreement, with MedHealth Supplies of South Africa, which sells to one of the world’s leading respiratory device suppliers. We have already received orders for over 1,000 units, with their first shipment sold out within 48 hours.
In December we produced a record 536 units in our in-house facility and with Innomax coming on-line in Q1 this will more than double production of X-PLOR. Of important note, even with the rapid increase in volume, the production quality of our in-house facility has been outstanding, with no units returned due to defects.
By 31 December 2022 the Company had shipped or received orders for 2,850 X-PLOR units with 1,226 units being shipped in 2022 (2021: 377). As at the year end, the Adjusted EBITDA1 loss is anticipated to be in line with market expectations and retained cash balances of $1.8 million, which together with inventory and inventory deposits, amounted to $11.9 million.
The next generation X-PLOR, launched in September 2022, has been well received by the market based upon its performance and reliability. It provides more oxygen by weight than any portable oxygen concentrator in its class and is the first POC with a mobile app that connects to phones, tablets, pulse oximeters and wearables (the NOMAD Biometric App).
The first DISCOV-RTM POCs expect to be launched for pre-market evaluation in Q1 2023, with full commercialisation anticipated in Q2. DISCOV-R is the first ambulatory pulse-dose and two-litre continuous flow POC in the world. Weighing c.40% less than any comparable dual flow oxygen concentrator on the market, the DISCOV-R produces nearly 3 times the oxygen by weight than its competition. Distributors are very excited about DISCOV-R and it is already receiving pre-orders. The DISCOV-R will also include the transformational NOMAD Biometric App.
In March 2022, we signed a manufacturing Master Supply Agreement (“MSA”) with InnoMax Medical Technology, Ltd (“InnoMax”) to manufacture the X-PLOR portable POC in China, more than doubling our manufacturing capacity in 2023 and enabling us to accelerate our international expansion by opening up markets in Asia and beyond. Innomax are anticipated to directly source most of their own components from the second half of 2023, which will also result in a significant margin improvement and reduction in the Company’s inventory levels.
Given the strong demand, the Group took the decision to transfer its US manufacturing in-house, to increase production output at high quality standards, and achieve a significant reduction in production costs. This was successfully completed at the end of July 2022, enabling the achievement of ISO:13485 accreditation. The manufacturing facility is already demonstrating the required product quality to build a significant customer base and repeat orders, underpinning the building of a strong brand reputation for our best-in-class technology.
Following this transition and having achieved ISO13485 accreditation, we are confident in having both the quality of manufacturing facilities and the inventory levels to increase production commensurate with market demand, as we expand our sales channels and are able to apply to distribute products internationally.
Robert Rauker, CEO of Belluscura plc, commented: “During the year we have made considerable progress. We have enhanced our production, quality accreditation and supply chain, positioning us well to deliver on the demand we are seeing for our devices, as we expand our distribution partners and geographical reach. Market reception for the next generation X-PLOR and Nomad App has been extremely positive, with an encouraging level of forward orders. We are very excited about the upcoming launch of the DISCOV-R, which we believe will be a transformational product, and we look to the future with confidence.”
Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payment expense, foreign exchange movements and non-recurring items.
For further information please contact:
Belluscura plc |
www.belluscura.com |
|
|
Robert Rauker, Chief Executive Officer |
via MHP |
|
|
Anthony Dyer, Chief Financial Officer |
|
||
|
|||
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
|
Neil Baldwin |
|
||
|
|||
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
|
James Serjeant / Nicholas Chambers |
|
||
|
|||
MHP (Financial PR and Investor Relations) |
Tel: +44 (0)20 3128 8100 |
|
|
Katie Hunt / Pete Lambie / Matthew Taylor |
Email: belluscura@mhpgroup.com |
|
|
|
|
||
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.